Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

Anita Kumar, K. S. Bantilan, A. P. Jacob, A. Park, S. F. Schoninger, C. Sauter, G. A. Ulaner, C. Casulo, M. Faham, K. A. Kong, R. K. Grewal, J. Gerecitano, A. Hamilton, P. Hamlin, M. Matasar, C. H. Moskowitz, A. Noy, M. L. Palomba, C. S. Portlock, A. YounesT. Willis, A. D. Zelenetz

Research output: Contribution to journalArticlepeer-review

Abstract

Limited information exists in mantle cell lymphoma (MCL) on the performance of next-generation sequencing–based assay of immunoglobulin gene rearrangements for minimal residual disease (MRD) assessment. Posttreatment peripheral blood samples were collected from 16 MCL patients and analyzed with the Adaptive Biotechnologies MRD assay, which identified early molecular relapse. We observed more sensitivity in the cellular versus acellular compartment.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2021
Externally publishedYes

Keywords

  • High-dose therapy
  • Minimal residual disease
  • Surveillance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue'. Together they form a unique fingerprint.

Cite this